CNOT12 and breast cancer: Taken together, these results indicate that low expression of TAB182-induced tumorigenesis and therapeutic resistance might be mediated through cancer stemness signaling pathways, and GLI2 shows the potential to be a target and leveraged to reduce cancer stemness in TAB182 low-expression breast cancers.